Author:
Locatelli Francesco,Roger Simon
Publisher
Oxford University Press (OUP)
Subject
Transplantation,Nephrology
Reference20 articles.
1. Chen ML, Shah V, Patnaik R, et al. (2001) Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res18:1645–1650.
2. Crommelin D, Bermejo T, Bissig M, et al. (2005) Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. EJHP-S11:11–17.
3. Schellekens H. (2005) Follow-on biologics: challenges of the “next generation”. Nephrol Dial Transplant20:[Suppl 4], iv31–iv36.
4. Casadevall N, Nataf J, Viron B, et al. (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med346:469–475.
5. Committee for medicinal products for human use (CHMP). Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency (EMEA) www.emea.eu.int, last accessed 23.11.2005.
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献